Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald in a report issued on Tuesday. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 123.33% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. Aegis assumed coverage on shares of Celldex Therapeutics in a research note on Monday. They set a “buy” rating for the company. Roth Capital set a $7.00 price target on shares of Celldex Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 2nd. Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. Brean Capital assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $16.00 price target for the company. Finally, Jefferies Group reaffirmed a “hold” rating and set a $5.00 price target (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Celldex Therapeutics has an average rating of “Buy” and an average price target of $7.75.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.07 on Tuesday. Celldex Therapeutics has a 52-week low of $2.85 and a 52-week high of $18.62. The company has a 50-day moving average of $3.63 and a 200 day moving average of $4.04. The company’s market capitalization is $409.22 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. The firm earned $2.20 million during the quarter, compared to the consensus estimate of $1.09 million. Celldex Therapeutics had a negative net margin of 1,923.41% and a negative return on equity of 49.27%. The company’s revenue for the quarter was up 115.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.32) earnings per share. Analysts predict that Celldex Therapeutics will post ($1.34) earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Marcus Capital LLC raised its stake in shares of Celldex Therapeutics by 0.5% in the third quarter. Marcus Capital LLC now owns 112,200 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 600 shares during the last quarter. Teachers Advisors LLC raised its stake in Celldex Therapeutics by 0.7% in the third quarter. Teachers Advisors LLC now owns 166,149 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 1,207 shares in the last quarter. Zacks Investment Management raised its stake in Celldex Therapeutics by 2.3% in the second quarter. Zacks Investment Management now owns 68,681 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,517 shares in the last quarter. National Planning Corp raised its stake in Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,650 shares in the last quarter. Finally, BlackRock Group LTD raised its stake in Celldex Therapeutics by 2.6% in the third quarter. BlackRock Group LTD now owns 70,520 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 1,767 shares in the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.